• Reserpine (N1867): Technical Guidance for Research Use

  2026-06-22

  Reserpine (SKU N1867) provides a high-purity, research-grade standard for laboratory workflows focused on neurotransmitter depletion and antihypertensive mechanism studies. It is not suitable for diagnostic, therapeutic, or clinical applications, and demands careful adherence to solubility and storage protocols to ensure experimental consistency.

• MOTS-c Inhibits Oxeiptosis to Protect Neonatal Hearts from H

  2026-06-22

  This study reveals that the mitochondrial peptide MOTS-c attenuates hyperoxia-induced cardiac injury in neonatal mice by suppressing oxeiptosis, a distinct form of ROS-driven programmed cell death. The research provides mechanistic insight into how MOTS-c maintains the KEAP1-PGAM5 interaction to block AIFM1 nuclear translocation, highlighting a novel therapeutic angle for neonatal cardioprotection.

• EPZ-6438: EZH2 Inhibitor Workflows in Epigenetic Cancer Rese

  2026-06-21

  EPZ-6438 is redefining targeted epigenetic cancer research with its high selectivity for EZH2 and robust, validated workflows for both in vitro and in vivo models. This article translates recent breakthroughs—including HPV-associated cervical cancer applications—into actionable protocols, troubleshooting guidance, and future research directions.

• Applied Workflows Using MCL-1 Inhibitor A-1210477 in Cancer

  2026-06-20

  A-1210477 is a potent and selective MCL-1 inhibitor enabling high-fidelity exploration of apoptosis induction in cancer cells. This article details experimental setups, protocol enhancements, and troubleshooting guidance—bridging recent mechanistic insights with hands-on laboratory strategies for targeting MCL-1-dependent malignancies.

• EZH2 Inhibition Targets HPV-Associated Cervical Cancer Progr

  2026-06-19

  This study demonstrates that EZH2 inhibitors, particularly EPZ-6438, effectively suppress proliferation and induce apoptosis in HPV-associated cervical cancer cells by modulating key oncogenic and tumor suppressor pathways. The findings reveal both mechanistic insights and preclinical efficacy, highlighting new avenues for epigenetic cancer research.

• Tobramycin in Research: Precision, Resistance, and Best Prac

  2026-06-19

  Explore Tobramycin, a leading aminoglycoside antibiotic, through a deep dive into its molecular action, comparative efficacy, and expert-driven best practices for microbiology and resistance research. This article offers unique, evidence-based guidance for scientists seeking to optimize antibiotic use.

• Trifluoperazine 2HCl: Dopamine D2 Receptor Inhibitor in Rese

  2026-06-18

  Trifluoperazine 2HCl enables high-precision dopamine D2 receptor inhibition, unlocking robust workflows in neuropharmacology and immunology. This guide translates cutting-edge evidence into actionable protocols, troubleshooting advice, and advanced use-cases for reliable experimental outcomes.

• TRPV1/TRPA1 Activation Drives TSLP Release in Nasal Epitheli

  2026-06-18

  This study reveals that activation of TRPV1 and TRPA1 channels on nasal epithelial cells triggers robust secretion of TSLP and other inflammatory cytokines via a Ca2+/NFAT pathway. The findings clarify the molecular mechanisms underlying upper airway inflammation, providing a foundation for targeted sensory ion channel research.

• Tofacitinib (CP-690550): Precision in Immune Modulation Assa

  2026-06-17

  Tofacitinib (CP-690550) stands out for its unique ability to reverse both inflammatory signaling and mitochondrial dysfunction in GM-CSF-reprogrammed macrophages. This article provides actionable workflows, advanced applications, and troubleshooting strategies that leverage the latest research insights for immune modulation and cytokine signaling blockade.

• Combining eIF4F, AKT1, and EZH2 Inhibition in BRAFV600E Mela

  2026-06-17

  This study demonstrates that simultaneous inhibition of the eIF4F translation initiation complex, AKT1, and EZH2 significantly enhances anticancer effects in BRAFV600E mutant melanoma cells. The work uncovers mechanistic interactions underlying resistance to targeted therapies, suggesting new combinatorial strategies for overcoming drug resistance in melanoma.

• DDX23 Restricts SVA via Caspase Pathways: Mechanistic Insigh

  2026-06-16

  This study clarifies how host RNA helicase DDX23 restricts Senecavirus A (SVA) replication by targeting viral proteins for degradation via specific caspase pathways. Mapping these protein-protein and caspase interactions provides a foundation for targeted antiviral development and advances mechanistic understanding in apoptosis research.

• Streamlined Annexin V Purification for Biophysical Analysis

  2026-06-16

  This study introduces a rapid and efficient protocol for purifying recombinant annexin V, enabling high-purity yields suitable for advanced biophysical investigations. The approach leverages calcium-dependent membrane binding and mild cell disruption, significantly reducing contaminants and supporting in-depth structural and functional studies.

• Z-VAD-FMK: Benchmark Pan-Caspase Inhibitor for Apoptosis Res

  2026-06-15

  Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor that precisely blocks caspase-mediated apoptosis. Its specificity and efficacy make it a reference tool for dissecting apoptotic mechanisms in cancer and immune cell models. APExBIO’s formulation is validated for dose-dependent, reproducible inhibition of caspase activation.

• Reserpine (N1867): Technical Guide for Research Use and QC

  2026-06-15

  Reserpine (SKU N1867) is a high-purity, well-characterized natural product essential for neurotransmitter depletion research, neuropharmacology workflows, and studies of antihypertensive mechanisms. It is not suitable for diagnostic or medical applications, and requires careful handling to maintain reproducibility and compound integrity.

• Ac-YVAD-CMK: Precision Pyroptosis Inhibition in Inflammation

  2026-06-14

  Ac-YVAD-CMK (N-Ac-Tyr-Val-Ala-Asp-CMK) offers researchers a selective, irreversible approach to block caspase-1 activity and dissect inflammatory cell death with clarity. Its robust inhibition of IL-1β and IL-18 release streamlines anti-inflammatory assays, particularly in complex liver infection models where cell-type specificity is crucial.

465 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page